Cat. No. 3061
Chemical Name: (15R)-6,17-Didemethoxy-15-methoxy-6-methyl-11-O-methyl-geldanamycin
Biological ActivityAnsamycin antibiotic compound that inhibits Hsp90 activity (IC50 = 2 μM) by binding to the ATP-binding site. Exhibits antitumor and cytocidal activities (IC50 ~ 0.4 μM) by causing degradation of key oncogenic client proteins such as ErbB2 and cRaf1. Displays higher affinity and potency than geldanamycin (Cat. No. 1368).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Ono et al (1982) Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. Gann. 73 938. PMID: 6186564.
Uehara et al (2003) Natural product origins of Hsp90 inhibitors. Curr.Cancer Drug Targets 3 325. PMID: 14529384.
Martin et al (2008) Molecular characterization of macbecin as an Hsp90 inhibitor. J.Med.Chem. 51 2853. PMID: 18357975.
If you know of a relevant citation for this product please let us know.
Keywords: Macbecin I, supplier, Hsp90, inhibitors, Heat, Shock, Protein, 90, MacbecinI, antibiotics
Find multiple products by catalog number
New Products in this Area
Binds mot-2; selectively cytotoxic in cancer cells
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.